Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis Adakveo® Receives Positive CHMP Opinion for the Prevention of Recurrent Vaso-Occlusive Crises in Patients with Sickle Cell Disease

Lead Product(s): Crizanlizumab

Therapeutic Area: Genetic Disease Product Name: Adakveo

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 24, 2020

Details:

CHMP opinion supported by data showing Adakveo significantly reduced the rate of vaso-occlusive crises, with patients on Adakveo spending fewer days in hospital.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis Receives EC Approval for Enerzair® Breezhaler®

Lead Product(s): Indacaterol acetate,Glycopyrronium Bromide,Mometasone Furoate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Enerzair Breezhaler

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2020

Details:

European Commission has approved once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with LABA/ICS1.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis Announces MET Inhibitor Tabrecta™ Approved in Japan for Advanced Non-Small Cell Lung Cancer with METex14

Lead Product(s): Capmatinib Hydrochloride

Therapeutic Area: Oncology Product Name: Tabrecta

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2020

Details:

Tabrecta demonstrated an overall response rate of 68% and 41% in treatment-naive and previously treated non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping (METex14) respectively.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps

Lead Product(s): Omalizumab

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Xolair

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 26, 2020

Details:

If approved, Xolair will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-IgE antibody specifically designed to target and block IgE.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis Discontinues Hydroxychloroquine Clinical Trial Based on Slow Enrollment, Remains Committed to Pandemic Research Efforts

Lead Product(s): Hydroxychloroquine Sulphate

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 19, 2020

Details:

Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made trial completion infeasible.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

FDA Approves First Treatment for Adult Onset Still’s Disease, a Severe and Rare Disease

Lead Product(s): Canakinumab

Therapeutic Area: Immunology Product Name: Ilaris

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 16, 2020

Details:

The U.S. Food and Drug Administration approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD).

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthm...

Lead Product(s): Indacaterol acetate,Glycopyrronium Bromide,Mometasone Furoate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Recipient: Sosei Heptares

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 05, 2020

Details:

Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily Tio in improving quality of life in people with uncontrolled asthma.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis PREVENT Data Show Cosentyx® Helps Patients Realize Early and Lasting Relief In Axial Spondyloarthritis

Lead Product(s): Secukinumab

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

Phase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 521.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis Kisqali® Shows Survival Benefit In HR+/HER2 Advanced Breast Cancer With Consistent Results In Patients With More Aggressive Diseas...

Lead Product(s): Ribociclib,Fulvestrant

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2020

Details:

Subgroup analysis shows Kisqali plus endocrine therapy extended life compared to endocrine therapy for patients with liver metastases – showing ~47% and 37% reduction in the risk of death in M7 and M3, respectively.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis Wins Conditional EU Approval for Gene Therapy Zolgensma

Lead Product(s): Onasemnogene abeparvovec-xioi

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Approved Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 19, 2020

Details:

Zolgensma is a transformative and highly innovative one-time gene therapy for a devastating and progressive genetic disease and is consistently priced worldwide under a value-based framework.

Find

Find Clinical Drug Pipeline Developments & Deals by Novartis Pharmaceuticals Corporation

Pipeline Prospector Find Drug Development Pipeline & Deal Updates

Companies By Therapeutic Area

Development Status

Novartis Pharmaceuticals Corporation

Novartis Adakveo® Receives Positive CHMP Opinion for the Prevention of Recurrent Vaso-Occlusive Crises in Patients with Sickle Cell Disease

Novartis Pharmaceuticals Corporation

Novartis Receives EC Approval for Enerzair® Breezhaler®

Novartis Pharmaceuticals Corporation

Novartis Announces MET Inhibitor Tabrecta™ Approved in Japan for Advanced Non-Small Cell Lung Cancer with METex14

Novartis Pharmaceuticals Corporation

Novartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps

Novartis Pharmaceuticals Corporation

Novartis Discontinues Hydroxychloroquine Clinical Trial Based on Slow Enrollment, Remains Committed to Pandemic Research Efforts

Novartis Pharmaceuticals Corporation

FDA Approves First Treatment for Adult Onset Still’s Disease, a Severe and Rare Disease

Novartis Pharmaceuticals Corporation

Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthm...

Novartis Pharmaceuticals Corporation

Novartis PREVENT Data Show Cosentyx® Helps Patients Realize Early and Lasting Relief In Axial Spondyloarthritis

Novartis Pharmaceuticals Corporation

Novartis Kisqali® Shows Survival Benefit In HR+/HER2 Advanced Breast Cancer With Consistent Results In Patients With More Aggressive Diseas...

Novartis Pharmaceuticals Corporation

Novartis Wins Conditional EU Approval for Gene Therapy Zolgensma